OSL:NYKD - Euronext Oslo - NO0010714785 - Common Stock - Currency: NOK
OSL:NYKD (5/6/2025, 2:53:15 PM)
2.59
+0.06 (+2.29%)
The current stock price of NYKD.OL is 2.59 NOK. In the past month the price increased by 16.04%. In the past year, price decreased by -81.97%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 19.07 | 305.33B | ||
1ABBV.MI | ABBVIE INC | 18.36 | 294.00B | ||
AMG.DE | AMGEN INC | 13.41 | 131.91B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.7 | 116.36B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1709.42 | 114.26B | ||
GIS.DE | GILEAD SCIENCES INC | 13.22 | 112.29B | ||
ARGX.BR | ARGENX SE | 375.03 | 35.04B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.40B | ||
IDP.DE | BIOGEN INC | 7.73 | 15.80B | ||
1MRNA.MI | MODERNA INC | N/A | 9.49B | ||
0QF.DE | MODERNA INC | N/A | 9.38B | ||
BIO.DE | BIOTEST AG | 64.92 | 1.67B |
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
NYKODE THERAPEUTICS ASA
Oslo Science Park, Gaustadalleen 21
Oslo OSLO NO
Employees: 179
Phone: 4722958193
The current stock price of NYKD.OL is 2.59 NOK. The price increased by 2.29% in the last trading session.
The exchange symbol of NYKODE THERAPEUTICS ASA is NYKD and it is listed on the Euronext Oslo exchange.
NYKD.OL stock is listed on the Euronext Oslo exchange.
9 analysts have analysed NYKD.OL and the average price target is 5.44 NOK. This implies a price increase of 110.04% is expected in the next year compared to the current price of 2.59. Check the NYKODE THERAPEUTICS ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NYKODE THERAPEUTICS ASA (NYKD.OL) has a market capitalization of 845.76M NOK. This makes NYKD.OL a Small Cap stock.
NYKODE THERAPEUTICS ASA (NYKD.OL) currently has 179 employees.
NYKODE THERAPEUTICS ASA (NYKD.OL) has a support level at 2.42 and a resistance level at 2.54. Check the full technical report for a detailed analysis of NYKD.OL support and resistance levels.
The Revenue of NYKODE THERAPEUTICS ASA (NYKD.OL) is expected to grow by 22.17% in the next year. Check the estimates tab for more information on the NYKD.OL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NYKODE THERAPEUTICS ASA (NYKD.OL) has a dividend yield of 40.49%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of NYKD.OL dividend history, reliability and sustainability.
NYKODE THERAPEUTICS ASA (NYKD.OL) will report earnings on 2025-05-14.
NYKODE THERAPEUTICS ASA (NYKD.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
ChartMill assigns a technical rating of 4 / 10 to NYKD.OL. When comparing the yearly performance of all stocks, NYKD.OL is a bad performer in the overall market: 94.74% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL. NYKD.OL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months NYKD.OL reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 90.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -25.29% | ||
ROE | -28.5% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 80% to NYKD.OL. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 17.8% and a revenue growth 22.17% for NYKD.OL